Pulmatrix (PULM) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual Meeting scheduled for December 18, 2024, will be held virtually with no in-person attendance permitted.
Stockholders as of October 31, 2024, are eligible to vote on key proposals, including director elections and auditor ratification.
Proxy materials are distributed primarily via Internet to reduce costs and environmental impact, with paper copies available upon request.
Voting can be conducted online, by phone, mail, or during the virtual meeting; proxies default to Board recommendations if no instructions are given.
Voting matters and shareholder proposals
Stockholders will vote on the election of two Class I directors for terms expiring in 2027.
Ratification of Marcum LLP as the independent registered public accounting firm for fiscal year 2024 is on the agenda.
Board recommends voting FOR all nominees and the auditor ratification.
Shareholder proposals for the 2025 meeting must be submitted by July 11, 2025, for proxy inclusion.
Board of directors and corporate governance
Board consists of five directors, divided into three classes with staggered terms.
All current directors are considered independent under Nasdaq rules.
Board committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined responsibilities and independent members.
No formal diversity policy, but a variety of perspectives and skills are considered in nominations.
No family relationships or material legal proceedings involving directors or executive officers.
Latest events from Pulmatrix
- Revenue fell to nil in 2025 as the company pivots to merger and asset monetization strategies.PULM
Q4 202526 Feb 2026 - Merger forms a well-funded biotech advancing targeted protein degraders for cancer and pain.PULM
M&A Announcement14 Jan 2026 - Q2 net loss narrowed, revenue fell to zero, and future depends on Cullgen merger approval.PULM
Q2 202517 Oct 2025 - Q3 revenue and losses fell, MannKind deal cut costs, and cash runway may last into Q4 2026.PULM
Q3 202417 Oct 2025 - Q3 2025 saw zero revenue, lower expenses, and a pending Cullgen merger with cash preservation focus.PULM
Q3 202516 Oct 2025 - Net loss widened on asset write-down as cost cuts and MannKind deal extended cash runway.PULM
Q2 202413 Jun 2025 - Pulmatrix narrows losses and prepares for a strategic merger with Cullgen in 2025.PULM
Q4 20246 Jun 2025 - Q1 2025 saw a $1.8M net loss, zero revenue, and operations focused on a Cullgen merger.PULM
Q1 20256 Jun 2025